Mechanisms of non-coenzyme action of thiamine: protein targets and medical significance

VA Aleshin, GV Mkrtchyan, VI Bunik - Biochemistry (Moscow), 2019 - Springer
Thiamine (vitamin B1) is a precursor of the well-known coenzyme of central metabolic
pathways thiamine diphosphate (ThDP). Highly intense glucose oxidation in the brain …

Precision treatment of beta-cell monogenic diabetes: a systematic review

RN Naylor, KA Patel, JLT Kettunen… - Communications …, 2024 - nature.com
Background Beta-cell monogenic forms of diabetes have strong support for precision
medicine. We systematically analyzed evidence for precision treatments for GCK-related …

Thiamine deficiency in pregnancy and lactation: implications and present perspectives

O Kareem, S Nisar, M Tanvir, U Muzaffer… - Frontiers in …, 2023 - frontiersin.org
During pregnancy, many physiologic changes occur in order to accommodate fetal growth.
These changes require an increase in many of the nutritional needs to prevent long-term …

Treatment of genetic defects of thiamine transport and metabolism

JD Ortigoza-Escobar, M Molero-Luis… - Expert Review of …, 2016 - Taylor & Francis
Introduction: Thiamine is a key cofactor for energy metabolism in brain tissue. There are four
major genetic defects (SLC19A2, SLC19A3, SLC25A19 and TPK1) involved in the …

[HTML][HTML] Identification of novel compound heterozygous variants in SLC19A2 and the genotype-phenotype associations in thiamine-responsive megaloblastic anemia

S Zhang, Y Qiao, Z Wang, J Zhuang, Y Sun, X Shang… - Clinica Chimica …, 2021 - Elsevier
Background and aims Thiamine-responsive megaloblastic anemia (TRMA), caused by
SLC19A2 loss-of-function variants, is characterized by the triad of megaloblastic anemia …

Recovered insulin production after thiamine administration in permanent neonatal diabetes mellitus with a novel solute carrier family 19 member 2 (SLC19A2) mutation: 硫胺素 …

C Sun, Z Pei, M Zhang, B Sun, L Yang… - Journal of …, 2018 - Wiley Online Library
摘要背景溶质运载蛋白家族19 成员2 (solute carrier family 19 member 2, SLC19A2)
基因缺陷是永久性新生儿糖尿病(permanent neonatal diabetes mellitus, PNDM) 的病因之一 …

[HTML][HTML] Systematic review of treatment of beta-cell monogenic diabetes

RN Naylor, KA Patel, JLT Kettunen, JME Männistö… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background: Beta-cell monogenic forms of diabetes are the area of diabetes care with the
strongest support for precision medicine. We reviewed treatment of hyperglycemia in GCK …

Thiamine responsive megaloblastic anemia: a novel SLC19A2 compound heterozygous mutation in two siblings

E Mozzillo, D Melis, M Falco, V Fattorusso… - Pediatric …, 2013 - Wiley Online Library
Thiamine responsive megaloblastic anemia (TRMA) is an autosomal recessive disease
caused by loss of function mutations in the SLC19A2 gene. TRMA is characterized by …

TRMA syndrome with a severe phenotype, cerebral infarction, and novel compound heterozygous SLC19A2 mutation: a case report

X Li, Q Cheng, Y Ding, Q Li, R Yao, J Wang, X Wang - BMC pediatrics, 2019 - Springer
Background Thiamine-responsive megaloblastic anemia (TRMA) is a rare autosomal
recessive inherited disease characterized by the clinical triad of megaloblastic anemia …

An Italian case series' description of thiamine responsive megaloblastic anemia syndrome: importance of early diagnosis and treatment

F Di Candia, V Di Iorio, N Tinto, R Bonfanti… - Italian Journal of …, 2023 - Springer
Background Individuals with thiamine-responsive megaloblastic anemia (TRMA) mainly
manifest macrocytic anemia, sensorineural deafness, ocular complications, and …